Difference between revisions of "Nelarabine (Arranon)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead")
m (Text replacement - "Category:Acute lymphocytic leukemia medications" to "Category:B-cell acute lymphoblastic leukemia medications")
Line 28: Line 28:
 
[[Category:Antimetabolites]]
 
[[Category:Antimetabolites]]
 
[[Category:Purine analogues]]
 
[[Category:Purine analogues]]
[[Category:Acute lymphocytic leukemia medications]]
+
[[Category:B-cell acute lymphoblastic leukemia medications]]
 
[[Category:Drugs FDA approved in 2005]]
 
[[Category:Drugs FDA approved in 2005]]

Revision as of 20:35, 22 January 2018

General information

Class/mechanism: Purine analog, antimetabolite. Nelarabine is metabolized to the cytotoxic deoxyguanosine analogue, 9-β-Darabinofuranosylguanine (ara-G), which is eventually converted to ara-GTP. ara-GTP is incorporated into DNA and leads to inhibition of DNA synthesis and cell death.[1][2]
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Brand names: Arranon, Atriance

References